Revolutionizing Multiple Myeloma Care: CAR T-Cell Therapy, Bispecific Antibodies, and Patient-Centered Strategies

This virtual symposium was broadcast in association with Oncology Pharmacists Connect: Winter 2024.

Program Description

In recent years, B-cell maturation antigen (BCMA) has become an attractive target in the treatment of multiple myeloma (MM). This program will focus on the applicability of approved and emerging BCMA-directed treatment, including both chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies (BsAbs), for patients with relapsed or refractory (RR) MM. Each modality has unique considerations associated with their use, which will be highlighted in featured patient cases. Given the broad choice of therapeutic strategies for RRMM, treatment selection is guided by a number of different factors, which necessitates that oncology pharmacists are prepared to develop individualized care plans for patients. Faculty experts will review real-world evidence for the use of CAR T cells and BsAbs in RRMM as well as ongoing investigations into their therapeutic sequencing, safety, and utility in combination with other agents.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: January 22, 2024
Expiration date: January 22, 2025

Time to complete activity: 1.0 hour

Learner level: Advanced
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Analyze the appropriateness of chimeric antigen receptor (CAR) T-cell therapy and novel bispecific antibodies (BsAbs) for relapsed/refractory multiple myeloma, considering patient- and disease-specific factors
• Assess the applicability of novel CAR T cells and BsAb treatment strategies in clinical practice
• Construct patient-centered care plans that incorporate tailored strategies for preventing, monitoring, and managing therapy-related toxicities of CAR T cells and BsAbs

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-24-004-H01-P. The activity is available for CE credit through January 22, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, has the following financial relationships with commercial interests to disclose:
Consultant: Genentech
Other (advisory board): KITE, Janssen, Pfizer, Jazz, BMS

James A. Davis, PharmD, BCOP, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Amy H. Seung, PharmD, BCOP, FHOPA, CHCP; Dipti Desai, PharmD, MBA, CHCP; Abigail Dill; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.


Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms